PBM
MSLE

Propel Bio Management’s Satellos Bioscience MSLE Stock Holding History

Propel Bio Management’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,145
Closed -$57.1K – 41
2026
Q1 		$57.1K Buy
+10,145
New +$99.7K 0.04% 38

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Propel Bio Management's MSLE Position: Q2 2026 in Review

Propel Bio Management sold out of Satellos Bioscience (MSLE) in Q2 2026, closing a stake of 10,145 shares — an estimated $57.1K sold.

Propel Bio Management first reported a position in MSLE in Q1 2026 and held it in 1 quarter. The position peaked at $57.1K in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Propel Bio Management reported no remaining Satellos Bioscience position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 10,145 Satellos Bioscience shares in Q2 2026, an estimated $57.1K.
  • Propel Bio Management first reported a position in Satellos Bioscience in Q1 2026 and held it in 1 quarter.
  • Propel Bio Management's Satellos Bioscience position peaked at $57.1K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.